Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. reports recurring business updates as a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. Company updates commonly address financial results, capital-structure actions, medical device portfolio development and subsidiary activity.
News also covers Lucid Diagnostics, PAVmed's commercial-stage cancer prevention diagnostics subsidiary, including EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device activity for patients at risk of esophageal precancer and cancer. Other recurring subjects include Veris Health digital health programs, the Veris Cancer Care Platform, implantable physiological monitor development and PAVmed's endoscopic esophageal imaging technology through Octeris.
PAVmed (Nasdaq: PAVM) has signed a non-binding letter of intent with Duke University to license groundbreaking endoscopic imaging technology through a new subsidiary. The technology combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT) to identify and treat esophageal precancer during upper endoscopy.
The technology, developed by Duke's Dr. Adam Wax in partnership with Dr. Nicholas Shaheen, has demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes. This innovative approach could replace traditional biopsies, enabling real-time detection and immediate treatment during the same endoscopic procedure.
Under the proposed agreement, PAVmed's subsidiary will receive exclusive worldwide license rights to the intellectual property. The company expects this technology to complement its EsoGuard diagnostic platform and attract strategic interest from endoscopic ablation companies.
PAVmed (NASDAQ: PAVM) reported its Q2 2025 financial results and business updates. Key highlights include Lucid Diagnostics processing 2,756 EsoGuard® tests with revenue of $1.2 million. The company reported a GAAP net loss of $13.3 million, or $(0.74) per share.
Significant developments include Lucid securing a CAC meeting for Medicare LCD coverage, strengthening its balance sheet with a $16.1 million public offering, and initiating testing under its first positive commercial insurance coverage with Highmark Blue Cross Blue Shield. Veris Health completed $2.5 million direct equity financing and established a strategic partnership with Ohio State's James Cancer Hospital.
The company ended Q2 2025 with cash and equivalents of $4.0 million, compared to $1.2 million at the end of 2024. Operating expenses were $4.7 million, including $0.2 million in stock-based compensation.
Lucid Diagnostics (Nasdaq: LUCD) reported its Q2 2025 financial results, highlighting $1.2 million in revenue from 2,756 processed EsoGuard® tests. The company strengthened its balance sheet through a public offering, netting $16.1 million and ending Q2 with over $30 million in proforma cash, extending runway into 2026.
Key developments include a scheduled Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 for Medicare coverage consideration, initiation of testing under Highmark Blue Cross Blue Shield coverage, and a partnership with Hoag healthcare network. The company reported a GAAP net loss of $7.9 million ($0.08 per share) and non-GAAP adjusted loss of $9.9 million ($0.10 per share) for Q2 2025.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences in August 2025.
The company will attend the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference for one-on-one meetings on August 11-12, 2025. Additionally, management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 2:30 PM ET in Boston, MA. The Canaccord presentation will be available via webcast with a 30-day replay option.
PAVmed (Nasdaq: PAVM), a diversified commercial-stage medical technology company, has scheduled a business update conference call and webcast for August 14, 2025, at 8:30 AM ET. During the call, Chairman and CEO Dr. Lishan Aklog will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present Q2 2025 financial results.
Investors can access the webcast through PAVmed's investor relations website. For telephone access, U.S. callers should dial 1-800-836-8184, while international callers can use 1-646-357-8785. A 30-day replay will be available on the company website following the call.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will host a business update conference call on August 13, 2025, at 8:30 AM ET.
The call will feature CEO Lishan Aklog discussing business operations and growth strategy, while CFO Dennis McGrath will present Q2 2025 financial results. Investors can access the webcast through luciddx.com or join by phone using specific dial-in numbers for U.S. and international callers.
PAVmed (Nasdaq: PAVM), a commercial-stage medical technology company, has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 19, 2026 to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
The notification does not immediately affect PAVmed's listing status, and its shares will continue trading on the Nasdaq Capital Market under the symbol "PAVM". The company has stated its intention to take appropriate actions to cure the deficiency and regain compliance before the extended deadline.
Lucid Diagnostics (NASDAQ:LUCD) announced that MolDX-participating Medicare Administrative Contractors will hold a critical Contractor Advisory Committee (CAC) meeting on September 4, 2025 to evaluate Medicare coverage for its EsoGuard® Esophageal DNA Test.
The virtual meeting will gather medical experts to reconsider Local Coverage Determination (LCD) L39256, following Lucid's November 2024 request. CEO Lishan Aklog highlighted the company's strong clinical evidence package and noted that nearly 40,000 patients have been referred for EsoGuard testing to date. The test's clinical utility is supported by professional society guidelines and peer-reviewed publications.
PAVmed (Nasdaq: PAVM) announced that its subsidiary Veris Health has completed a $2.5 million private placement equity financing. The financing involved selling Veris Health common stock at $1.40 per share, with a pre-money valuation of $35 million.
Investors received warrants to purchase additional shares at $1.40 per share, callable within 60 days of FDA clearance. This funding follows a previous $2.4 million financing earlier this year. The proceeds will support the development of Veris' implantable physiological monitor through FDA clearance, expected in 2026, and general corporate purposes.